论文部分内容阅读
目的:探讨爱普列特联合特拉唑嗪治疗前列腺增生的临床疗效。方法:选取我院接收的92例前列腺增生患者作为本次的研究对象,所有患者均行爱普列特联合特拉唑嗪治疗,并对其治疗效果进行回顾性分析总结。结果:治疗6个月后所有患者的国际前列腺症状评分(IPSS)、前列腺体积(PV)、最大尿流量(Qmax)、剩余尿量(RU)均较治疗前有明显改善(P<0.01),有统计学意义。结论:将爱普列特联合特拉唑嗪应用于前列腺增生患者的治疗中具有较高的应用价值,有助于改善患者症状,值得推广应用。
Objective: To investigate the clinical efficacy of Epristeride combined with terazosin in the treatment of benign prostatic hyperplasia. Methods: 92 cases of benign prostatic hyperplasia received in our hospital were selected as the research object. All patients were treated with Epristeride and terazosin, and the therapeutic effect was retrospectively analyzed and summarized. Results: IPSS, PV, Qmax and RU were significantly improved (P <0.01) in all patients after 6 months of treatment, There is statistical significance. Conclusion: The application of Epristeride and Terazosin in the treatment of benign prostatic hyperplasia patients has high value, which can help to improve the symptoms of patients and is worth popularizing and applying.